Adcetris

Description

Indications for the drug Adcetris

– treatment of patients with relapsed/refractory CD30+ Hodgkin lymphoma after autologous stem cell transplantation or after at least two lines of previous therapy, when autologous stem cell transplantation or combination chemotherapy are not considered as a treatment option;

– treatment of patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression of the disease* after autologous stem cell transplantation;

– treatment of patients with relapsed/refractory systemic anaplastic large cell lymphoma.

Active ingredient: brentuximab vedotin

Prescription medicine